Key statistics dashboard for Marker Therapeutics, Inc. (MRKR). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology.
Stock Data
| Price | $1.14 |
| Market Cap | $19M |
| Enterprise Value | $7.7M |
| Beta | 1.47 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -2.38 |
| Price / Book | 1.81 |
| P/S | 15.42 |
| EV/EBITDA | -0.88 |
| EV/Sales | 6.23 |
| EV/FCF | -0.79 |
| P/FCF | -1.95 |
| Earnings Yield | -39.55% |
| FCF Yield | -51.33% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | -320.83% |
| EBIT Margin | -707.46% |
| EBITDA Margin | -707.46% |
| Operating Margin | -868.95% |
| Net Margin | -706.23% |
| Return on Equity | -56.96% |
| Return on Assets | -59.70% |
| Return on Invested Capital | -87.91% |
| Return on Capital Employed | -88.07% |
Financial Health
| Current Ratio | 6.03 |
| Quick Ratio | 6.03 |
| Cash Ratio | 4.68 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 1.30 |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -32.65 |
Per-Share Data
| Revenue per share | 0.06 |
| Book Value per share | 0.63 |
| Cash per share | 0.59 |
| FCF per share | -0.51 |
| Tangible Book Value per share | 0.63 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 1 |
| Buy | 2 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Related companies: AEON · BOLT · CLRB · COCP · EVGN · GLTO · IMNN
Explore sector: Healthcare · Biotechnology
More sections of MRKR: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks